FGF-1 vs PTD-DBM

Binds all four FGFR subtypes (broadest binding of FGF family). Activates MAPK and PI3K downstream pathways. Promotes fibroblast proliferation, angiogenesis, and hair follicle cycling into anagen phase.

FGF-1 (fibroblast growth factor 1; acidic FGF; aFGF) is an endogenous 155-amino-acid heparin-binding growth factor and the prototypic member of the 22-member FGF family, expressed in diverse tissues where it stimulates cell proliferation, survival, and migration through tyrosine kinase receptor (FGFR1-4) signaling, with particularly important roles in angiogenesis, wound healing, and tissue repair. FGF-1 activates FGFR to initiate MAPK/ERK, PI3K/Akt, and PLCgamma signaling cascades driving endothelial cell sprouting and neovascularization; in ischemic tissues, FGF-1 is a potent inducer of therapeutic angiogenesis, stimulating new vessel formation to restore perfusion in peripheral arterial disease and critical limb ischemia. A Phase 2 randomized controlled trial of intramuscular gene-encoded FGF-1 delivery (NV1FGF, a non-viral plasmid vector) in critical limb ischemia demonstrated improved amputation-free survival in human subjects, providing clinical evidence for FGF-1 pathway activity; this gene therapy approach is distinct from direct recombinant FGF-1 protein administration, and no protein therapy form has completed Phase 3 trials. Recombinant FGF-1 protein has no FDA approval as a standalone therapeutic; the clinical evidence base references gene-encoded delivery rather than the protein itself, and research-grade FGF-1 is used primarily as a cell culture supplement and tissue engineering scaffold factor rather than as a therapeutically administered agent.

Contains a protein transduction domain enabling intracellular delivery. Disrupts Dishevelled-Axin protein interaction, preventing β-catenin degradation and activating Wnt target genes essential for hair follicle cycling and new follicle neogenesis.

PTD-DBM is a synthetic peptide combining a protein transduction domain (PTD) with a Dishevelled-binding motif (DBM) derived from the CXXC5 protein, engineered to penetrate cells and disrupt the CXXC5-Dishevelled protein-protein interaction that normally suppresses Wnt/beta-catenin signaling, with the goal of reactivating the Wnt pathway in hair follicle stem cells to promote follicle cycling and hair regrowth in androgenetic alopecia. The proposed mechanism targets a specific negative regulatory checkpoint: CXXC5 binds Dishevelled to prevent beta-catenin nuclear translocation; the PTD-DBM peptide competitively disrupts this interaction to restore Wnt pathway activity in follicular dermal papilla cells, a mechanism demonstrated to stimulate hair follicle activation in preclinical mouse models of hair loss. No published human clinical trials, pharmacokinetic studies, or Phase 1 safety data for PTD-DBM have been indexed in PubMed; available indexed literature consists of preclinical cell-based and mouse studies examining the CXXC5/Wnt/DHT signaling axis in androgenetic alopecia, with no human data characterizing this compound's safety, bioavailability, or efficacy. PTD-DBM has no FDA approval or approved indication in any jurisdiction; it is a research compound with a well-defined preclinical mechanistic rationale targeting the Wnt pathway but no published human data, and its development status as a clinical candidate has not been established in the indexed scientific literature.